| Title |
Doxylamine succinate–pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview
|
|---|---|
| Published in |
International Journal of Women's Health, April 2014
|
| DOI | 10.2147/ijwh.s46653 |
| Pubmed ID | |
| Authors |
Nina Nuangchamnong, Jennifer Niebyl |
| Abstract |
Nausea and vomiting in pregnancy (NVP) is common and often undertreated, in part due to fears of adverse effects of medications on the fetus during early pregnancy. In April 2013, the US Food and Drug Administration (FDA) approved doxylamine succinate 10 mg and pyridoxine hydrochloride (a vitamin B6 analog) 10 mg as a delayed-release combination pill called Diclegis for the treatment of NVP. Diclegis is currently the only medication that is FDA-approved for the indication of NVP. This review addresses the historical context, safety, efficacy, pharmacology, and practical role of doxylamine and pyridoxine for the management of NVP. The reintroduction of this doxylamine-pyridoxine combination pill into the American market fills a therapeutic gap in the management of NVP left by the removal of the same active drugs marketed over 30 years ago in the form of Bendectin. The substantial amount of safety data accumulated over the years makes it one of the few drugs that qualify for FDA Pregnancy Category A status. In the hierarchical approach to pharmacological treatment of NVP, the combination of doxylamine and pyridoxine should thus be first-tier. |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 88 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 13% |
| Student > Doctoral Student | 12 | 13% |
| Student > Bachelor | 11 | 12% |
| Researcher | 9 | 10% |
| Other | 6 | 7% |
| Other | 17 | 19% |
| Unknown | 23 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 37% |
| Nursing and Health Professions | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 9% |
| Agricultural and Biological Sciences | 6 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 7 | 8% |
| Unknown | 24 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 61. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2024.
All research outputs
#610,380
of 23,213,531 outputs
Outputs from International Journal of Women's Health
#34
of 795 outputs
Outputs of similar age
#6,094
of 227,153 outputs
Outputs of similar age from International Journal of Women's Health
#4
of 28 outputs
Altmetric has tracked 23,213,531 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 795 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,153 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.